Edgewise Therapeutics – 2025-12-19 - Increase Confidence 7/10

EWTX – Increase in Days/Weeks

Edgewise Therapeutics burned $110.3M in free cash flow over the past year, reflecting heavy R&D investment, while recent updates confirm $563.3M in cash as of Q3 2025 and imminent clinical catalysts in Q4 2025 and beyond.

Why This Matters

The company remains pre-revenue with no near-term path to profitability, but its financial runway—over $500M in cash—fully funds operations into 2027, eliminating near-term dilution risk. With key data readouts expected soon, including the CIRRUS-HCM update in Q4 2025 and multiple Phase I/II milestones in early 2026, investor sentiment is poised for a positive re-rating on any favorable signal.

Key Insights

• Cash Position: $563.3M as of Sept 30, 2025, per Q3 report — sufficient to fund through major clinical inflection points
• News Impact: CIRRUS-HCM update expected in Q4 2025 and EDG-7500 Phase 3 planning signal pipeline momentum
• Risk/Offset: No revenue and negative FCF; stock sensitive to trial setbacks or safety signals

Practical Implications

• Bull Case: Positive CIRRUS-HCM update or accelerated EDG-7500 development → 15–20% upside in weeks
• Bear Case: Lack of data clarity or insider selling pressure from Rule 144 filings → short-term pullback to $22–23
• Confidence: 7/10 – High cash and catalysts offset fundamental risks in near term

Prediction: increase

Reference:

• https://www.futunn.com/stock/EWTX-US/announcement